You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Trastuzumab emtansine

Showing 1 - 25 of 1,037
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))

Recruiting
  • Advanced Breast Cancer
  • +2 more
  • Trastuzumab Emtansine (T-DM1)
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,

Not yet recruiting
  • HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
  • (no location specified)
Nov 7, 2023

Trastuzumab Emtansine as Therapy in Chinese HER2 Positive

Not yet recruiting
  • Breast Cancer
  • Trastuzumab emtansine
  • (no location specified)
Jul 13, 2023

Metastatic Solid Tumor, Brain Metastases Trial in Houston (Trastuzumab emtansine, Tucatinib)

Not yet recruiting
  • Metastatic Solid Tumor
  • Brain Metastases
  • Houston, Texas
    M D Anderson Cancer Center
Dec 30, 2022

Ado-trastuzumab Emtansine-Induced Peripheral Neuropathy in

Recruiting
  • Breast Neoplasm
    • Rochester, Minnesota
      Mayo Clinic Minnesota
    Jun 12, 2023

    Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial

    Recruiting
    • Metastatic Salivary Gland Carcinoma
    • +4 more
    • New York, New York
      Memorial Sloane Kettering Cancer Center
    Jan 11, 2023

    HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,

    Completed
    Has Results
    • HER2 Positive Breast Carcinoma
    • +6 more
    • Palo Alto, California
      Stanford University, School of Medicine
    Sep 22, 2022

    Salivary Gland Cancer, HER2 Gene Mutation Trial in Boston (Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy,

    Recruiting
    • Salivary Gland Cancer
    • HER2 Gene Mutation
    • Ado-trastuzumab (T) emtansine (T-DM1)
    • +2 more
    • Boston, Massachusetts
    • +1 more
    Jan 2, 2023

    NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

    Terminated
    • Carcinoma, Non-Small-Cell Lung
    • Maastricht, Limburg, Netherlands
    • +4 more
    Nov 7, 2022

    Breast Cancer Trial in Boston (T-DM1, Pembrolizumab)

    Active, not recruiting
    • Breast Cancer
    • Boston, Massachusetts
    • +1 more
    Jul 25, 2022

    Tyrosine Kinase Inhibitors in Trastuzumab Emtansine Resistant

    Recruiting
    • Breast Cancer
    • Nanjing, Jiangsu, China
      Jiangsu Provincial People's Hospital
    Feb 7, 2022

    Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States

    Withdrawn
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +3 more
    • Yuma, Arizona
    • +5 more
    May 25, 2022

    Solid Tumor Cancers, Lung Cancer, Bladder Cancer Trial in United States (ado-trastuzumab emtansine)

    Recruiting
    • Solid Tumor Cancers
    • +3 more
    • ado-trastuzumab emtansine
    • Basking Ridge, New Jersey
    • +6 more
    Mar 1, 2022

    Breast Cancer Trial in East Melbourne, Seoul (Placebo, Venetoclax, Trastuzumab emtansine)

    Terminated
    Has Results
    • Breast Cancer
    • Placebo
    • +2 more
    • East Melbourne, Victoria, Australia
    • +2 more
    Oct 8, 2021

    HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy Trial (Trastuzumab Emtansine for Injection, Pyrotinib Maleate

    Not yet recruiting
    • HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
    • Trastuzumab Emtansine for Injection
    • Pyrotinib Maleate Tablets
    • (no location specified)
    Sep 30, 2022

    Trastuzumab Emtansine in HER2-positive Breast Cancer Residual

    Recruiting
    • Breast Cancer
    • Trastuzumab emtansine
    • Prato, Firenze, Italy
    • +27 more
    Mar 2, 2023

    Breast Cancer, Heart Failure Trial in Canada, Russian Federation (Trastuzumab, Pertuzumab, Trastuzumab emtansine)

    Recruiting
    • Breast Cancer
    • Heart Failure
    • Hamitlon, Ontario, Canada
    • +3 more
    Jun 21, 2022

    Breast Cancer Trial (Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F

    Not yet recruiting
    • Breast Cancer
    • Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)
    • Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
    • (no location specified)
    Feb 22, 2023

    HER2 Mutant NSCLC, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation Trial (ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki,

    Not yet recruiting
    • HER2 Mutant Non-small Cell Lung Cancer
    • +3 more
    • (no location specified)
    Dec 6, 2022

    Breast Cancer, HER2-positive Breast Cancer Trial in United States (trastuzumab-emtansine, Trastuzumab SC, Paclitaxel)

    Recruiting
    • Breast Cancer
    • HER2-positive Breast Cancer
    • trastuzumab-emtansine
    • +2 more
    • Stamford, Connecticut
    • +16 more
    Jun 20, 2022

    Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer Trial (Trastuzumab,

    Recruiting
    • Brain Metastases
    • +2 more
    • Saint Louis, Missouri
    • +1 more
    Nov 8, 2022

    Breast Cancer Trial in Houston, Sugar Land (T-DM1, Trastuzumab, Lapatinib)

    Completed
    Has Results
    • Breast Cancer
    • Houston, Texas
    • +2 more
    Aug 27, 2021

    NSCLC Trial in London (MPDL3280A, Vemurafenib, Alectinib)

    Recruiting
    • Non-small Cell Lung Cancer
    • London, United Kingdom
      Univeristy College London Hospital
    Feb 22, 2022

    HER2+ Breast Cancer Trial in Xi'an (Trastuzumab, Pertuzumab, Nab paclitaxel)

    Recruiting
    • HER2+ Breast Cancer
    • Xi'an, Shaanxi, China
    • +1 more
    Jun 20, 2022

    Cancer, Tumors, Tumors Trial in Denmark (Alectinib, Atezolizumab, Avelumab)

    Recruiting
    • Cancer
    • +3 more
    • Aalborg, Denmark
    • +6 more
    Oct 25, 2022